Abstract
We performed a meta-analysis to evaluate the efficacy outcomes of different pomalidomide (Pom) regimens in relapsed/refractory multiple myeloma (RRMM). Three-drug Pom regimens yielded double the response rates compared to Pom + low-dose dexamethasone (LoDex), and notably better outcomes than bortezomib + Pom + LoDex and carfilzomib + Pom + LoDex. Ongoing trials of Pom with various monoclonal antibodies will provide further insight into the role of pomalidomide for RRMM.
Original language | English (US) |
---|---|
Pages (from-to) | 447-461 |
Number of pages | 15 |
Journal | Clinical Lymphoma, Myeloma and Leukemia |
Volume | 19 |
Issue number | 7 |
DOIs | |
State | Published - Jul 2019 |
Keywords
- Adverse event
- Immunomodulator
- Outcome
- Overall response
- Pom-dex
ASJC Scopus subject areas
- Hematology
- Oncology
- Cancer Research